Literature DB >> 11879573

Intravirion display of a peptide corresponding to the dimer structure of protease attenuates HIV-1 replication.

M Cartas1, S P Singh, D Serio, T A Rizvi, V S Kalyanaraman, C S Goldsmith, S R Zaki, I T Weber, A Srinivasan.   

Abstract

Current treatment of HIV-1-infected individuals involves the administration of several drugs, all of which target either the reverse transcriptase or the protease activity of the virus. Unfortunately, the benefits of such treatments are compromised by the emergence of viruses exhibiting resistance to the drugs. This situation warrants new approaches for interfering with virus replication. Considering the activation of protease in the virus particles, a novel strategy to inhibit HIV-1 replication was tested targeting the dimerization domain of the protease. To test this idea, we have selected four residues from the C terminus of HIV-1 protease that map to the dimer interface region of the enzyme. We have exploited Vpr to display the peptides in the virus particles. The chimeric Vpr exhibited expression and virion incorporation similar to wildtype Vpr. The virus derived from the HIV-1 proviral DNA containing chimeric Vpr sequences registered a reduced level of replication in CEM and CEM X 174 cells in comparison with viruses containing wildtype Vpr. Similar results were observed in a single-round replication assay. These results suggest that the intravirion display of peptides targeting viral proteins is a powerful approach for developing antiviral agents and for dissecting the dynamic interactions between structural proteins during virus assembly and disassembly.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11879573     DOI: 10.1089/104454901753438615

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  2 in total

Review 1.  Nanotechnology-based approaches for the development of diagnostics, therapeutics, and vaccines.

Authors:  Alagarsamy Srinivasan; Anshu Rastogi; Velpandi Ayyavoo; Shiv Srivastava
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-06

2.  Targeting human immunodeficiency virus type 1 assembly, maturation and budding.

Authors:  Johanna Wapling; Seema Srivastava; Miranda Shehu-Xhilaga; Gilda Tachedjian
Journal:  Drug Target Insights       Date:  2007-07-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.